{"organizations": [], "uuid": "8865a5e305e242293d1ac7b2cc916a644d2d0b8b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/11/globe-newswire-spectral-announces-first-quarter-results.html", "country": "US", "domain_rank": 767, "title": "Spectral Announces First Quarter Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.002, "site_type": "news", "published": "2018-05-11T16:00:00.000+03:00", "replies_count": 0, "uuid": "8865a5e305e242293d1ac7b2cc916a644d2d0b8b"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/11/globe-newswire-spectral-announces-first-quarter-results.html", "ord_in_thread": 0, "title": "Spectral Announces First Quarter Results", "locations": [], "entities": {"persons": [], "locations": [{"name": "toronto", "sentiment": "none"}], "organizations": [{"name": "spectral medical inc.", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "TORONTO, May 11, 2018 (GLOBE NEWSWIRE) -- Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its unaudited financial results for the first quarter ended March 31, 2018.\nFinancial Review\nRevenue for the three months ended March 31, 2018 was $1,163,000 compared to $910,000 for the same three-month period last year. First quarter revenues were consistent with prior year levels.\nOperating costs for the quarter ended March 31, 2018 were $1,877,000 compared to $1,903,000 for the same period in 2017. Most of the Company’s expenses are incurred in its Phase III clinical trial and regulatory program and will vary depending on the timing and determination of the regulatory path forward. Apart from clinical trial and regulatory activities, the Company continues to maintain a low cost operating structure for its base business operations.\nLoss for the quarter ended March 31, 2018 was $714,000 ($0.003 per share) compared to $993,000 ($0.005 per share) for the same quarter last year.\nThe Company concluded the first quarter of 2018 with cash on hand of $982,000 compared to $1,449,000 as of December 31, 2017. After closing of its private placement financing subsequent to the quarter end, the Company had $5,842,000 of cash to pursue its regulatory approval for the PMX cartridge, working capital, and general corporate purposes.\nThe total number of shares outstanding for the Company was 207,796,522 as at March 31, 2018.\nAbout Spectral\nSpectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.\nPMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 150,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 350,000 patients are diagnosed with severe sepsis and septic shock in North America each year. Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit www.spectraldx.com\nForward-looking statement\nInformation in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.\nThe TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.\nFor further information, please contact:\nPaul Walker\nPresident and CEO\nSpectral Medical Inc.\n416-626-3233 ext. 2100\npwalker@spectraldx.com Ali Mahdavi\nCapital Markets & Investor Relations\n416-962-3300\nam@spinnakercmi.com\nSpectral Medical Inc.\nCondensed Interim Consolidated Statements of Financial Position\n(Unaudited) (in thousands of Canadian dollars) March 31 2018 December 31 2017 January 01 2017 Restated (Note 7) Restated (Note 7) $ $ $ Assets Current assets Cash 982 1,449 5,080 Trade and other receivables 857 881 642 Inventories 298 191 244 Prepayments and other assets 249 73 166 Contract asset 126 - - 2,512 2,594 6,132 Non-current assets Property and equipment 526 570 634 Intangible asset 303 309 334 Total assets 3,341 3,473 7,100 Liabilities Current liabilities Trade and other payables 514 612 1,112 Contract liability 3 3 6 Total liabilities 517 615 1,118 Equity Share capital 63,345 63,225 63,084 Contributed surplus 7,981 7,849 7,849 Share-based compensation 5,474 4,914 4,103 Warrants - 132 132 Deficit (73,976 ) (73,262 ) (69,186 ) Total equity 2,824 2,858 5,982 Total liabilities and equity 3,341 3,473 7,100\nSpectral Medical Inc.\nCondensed Interim Consolidated Statements of Loss and Comprehensive Loss\nFor the three months ended March 31, 2018 and 2017\n(Unaudited) (in thousands of Canadian dollars, except for share and per share data) 2018 2017 Restated (Note 7) $ $ Revenue 1,163 910 Expenses Changes in inventories of finished goods and work- in-process 24 15 Raw materials and consumables used 68 52 Employee benefits 1,165 1,080 Consulting and professional fees 210 320 Product development - 50 Regulatory and investor relations 198 96 Travel and entertainment 28 86 Depreciation and amortization 62 54 Foreign exchange (gain) loss (30 ) 3 Other expenses 152 147 1,877 1,903 Loss and comprehensive loss for the period (714 ) (993 ) Basic and diluted loss per common share (0.003 ) (0.005 ) Weighted average number of common shares outstanding 207,584,717 207,165,587\nSpectral Medical Inc.\nCondensed Interim Consolidated Statements of Changes in Equity\nFor the three months ended March 31, 2018 and 2017\n(Unaudited) (in thousands of Canadian dollars) Issued capital Contributed surplus Share-based compensation Warrants Deficit Total equity Number $ $ $ $ $ $ Balance, January 1, 2017 207,165,587 63,084 7,849 4,103 132 (69,346 ) 5,822 Change in accounting policies - - - - - 160 160 Restated equity, January 1, 2017 207,165,587 63,084 7,849 4,103 132 (69,186 ) 5,982 Loss and comprehensive loss for the period, restated - - - - - (993 ) (993 ) Share-based compensation - - - 310 - - 310 Balance, March 31, 2017 207,165,587 63,084 7,849 4,413 132 (70,179 ) 5,299 Share options exercised 293,435 141 - (57 ) - - 84 Loss and comprehensive loss for the period, restated - - - - - (3,083 ) (3,083 ) Share-based compensation - - 558 - 558 Balance, December 31, 2017 207,459,022 63,225 7,849 4,914 132 (73,262 ) 2,858 Balance, January 1, 2018 207,459,022 63,225 7,849 4,914 132 (73,285 ) 2,835 Change in accounting policies - - - - - 23 23 Restated equity, January 1, 2018 207,459,022 63,225 7,849 4,914 132 (73,262 ) 2,858 Share options exercised 337,500 120 - (49 ) - - 71 Warrant expiry - - 132 - (132 ) - - Loss and comprehensive loss for the period - - - - - (714 ) (714 ) Share-based compensation - - - 609 - - 609 Balance, March 31, 2018 207,796,522 63,345 7,981 5,474 - (73,976 ) 2,824\nSpectral Medical Inc.\nCondensed Interim Consolidated Statements of Cash Flows\nFor the three months ended March 31, 2018 and 2017\n(Unaudited) (in thousands of Canadian dollars) 2018 2017 Restated (Note 7) $ $ Cash flow provided by (used in) Operating activities Loss and comprehensive loss for the period (714 ) (993 ) Adjustments for: Depreciation on property and equipment 56 48 Amortization of intangible asset 6 6 Share-based compensation 609 310 Changes in items of working capital : Trade and other receivables 24 (150 ) Inventories (107 ) (15 ) Prepayments and other assets (176 ) (133 ) Contract asset (126 ) - Trade and other payables (98 ) (354 ) Contract liability - (4 ) Net cash used in operating activities (526 ) (1,285 ) Investing activities Property and equipment expenditures (12 ) (81 ) Net cash used in investing activities (12 ) (81 ) Financing activities Share options exercised 71 - Net cash provided by financing activities 71 - Decrease in cash (467 ) (1,366 ) Cash, beginning of period 1,449 5,080 Cash, end of period 982 3,714\nSource:Spectral Medical Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/9516c02b-7f3b-41c0-bac1-a037af9a3240"], "published": "2018-05-11T16:00:00.000+03:00", "crawled": "2018-05-11T16:30:39.000+03:00", "highlightTitle": ""}